JohnHowardRexMD

Physician

Dr. Rex is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1987 - 1991
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1984 - 1987
Baylor College of MedicineClass of 1982

PubMed

277 citations
An insight into the antifungal pipeline: selected new molecules and beyond.
Luis Ostrosky-Zeichner, Arturo Casadevall, John N. Galgiani, Frank C. Odds, John H. Rex
Nature Reviews. Drug Discovery. 2010-09-01
60 citations
Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
Adrian Towse, C. Hoyle, Jonathan Goodall, Mark Hirsch, Jorge Mestre-Ferrandiz
Health Policy. 2017-10-01
24 citations
Designing development programs for non-traditional antibacterial agents.
John H. Rex, Holly Fernandez Lynch, I. Glenn Cohen, Jonathan J. Darrow, Kevin Outterson
Nature Communications. 2019-07-31

F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal InfectionsDecember 19th, 2022
F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with OlorofimOctober 21st, 2022
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus ChemotherapyOctober 25th, 2023
Join now to see all